YMAB vs. CRMD, EBS, EGRX, TSVT, RENB, OMER, LFCR, ALXO, ALLK, and STOK
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include CorMedix (CRMD), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX), 2seventy bio (TSVT), Renovaro Biosciences (RENB), Omeros (OMER), Lifecore Biomedical (LFCR), ALX Oncology (ALXO), Allakos (ALLK), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical preparations" industry.
Y-mAbs Therapeutics vs.
Y-mAbs Therapeutics (NASDAQ:YMAB) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
CorMedix has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Y-mAbs Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
In the previous week, Y-mAbs Therapeutics' average media sentiment score of 0.00 beat CorMedix's score of -0.27 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.
Y-mAbs Therapeutics presently has a consensus target price of $12.63, indicating a potential upside of 143.26%. CorMedix has a consensus target price of $12.33, indicating a potential upside of 244.51%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Y-mAbs Therapeutics.
Y-mAbs Therapeutics has a net margin of -45.96% compared to CorMedix's net margin of -45,003.03%. Y-mAbs Therapeutics' return on equity of -36.37% beat CorMedix's return on equity.
Y-mAbs Therapeutics received 105 more outperform votes than CorMedix when rated by MarketBeat users. Likewise, 59.04% of users gave Y-mAbs Therapeutics an outperform vote while only 50.00% of users gave CorMedix an outperform vote.
45.5% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 35.0% of CorMedix shares are held by institutional investors. 21.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 3.6% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Y-mAbs Therapeutics beats CorMedix on 10 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Y-mAbs Therapeutics Competitors List
Related Companies and Tools